NEW YORK (TheStreet) -- Good news for Catalyst Pharmaceutical Partnersa Monday is bad news for patients with a rare neuromuscular disease and the U.S. health care system. Catalyst reported positive results from a phase III study of Firdapseaas a treatment foraLambert-Eaton Myasthenic Syndrome (LEMS), a progressive, muscle-weakening disease. Treatment with Firdapse improved LEMS symptoms compared to a placebo.aWith these data, Catalyst intends to seek Food and Drug Administration approval for Firdapse early next year.
Catalyst Pharma Closer To Unconscionable Price Hike For Rare-disease Drug
twocents@thestreet.com (Adam Feuerstein), The Street
Tue, 09/30/2014 - 4:20am
Topics: york thestreet good catalyst pharmaceutical partnersa monday iii myasthenic syndrome lems food drug administration alcobra investors nervous about coming drug study doctors jersey biomarin questcor mallinckrodt a and catalyst bio almost-toxic debt raise responsible stock slide if jacobus cprx drugs monday catalyst catalyst firdapse lems lems read u.s pharmaceuticals europe fda click price patients company treatment clinical news disease approval free trial work speak years active orphan year cost rights symptoms publicly
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more